当前位置:
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Pyrotinib shows activity in metastatic breast cancer
The Lancet Oncology ( IF 41.6 ) Pub Date : 2017-09-21 , DOI: 10.1016/s1470-2045(17)30755-6 Elizabeth Gourd
The Lancet Oncology ( IF 41.6 ) Pub Date : 2017-09-21 , DOI: 10.1016/s1470-2045(17)30755-6 Elizabeth Gourd
Pyrotinib, an irreversible pan-ErbB inhibitor, shows promising antitumour activity in patients with HER2-positive metastatic breast cancer, according to the results of a recent phase 1 trial.
中文翻译:
吡罗替尼在转移性乳腺癌中显示活性
根据最近的一项1期临床试验的结果,吡罗替尼是一种不可逆的pan-ErbB抑制剂,在HER2阳性转移性乳腺癌患者中显示出有希望的抗肿瘤活性。
更新日期:2017-09-21
中文翻译:
吡罗替尼在转移性乳腺癌中显示活性
根据最近的一项1期临床试验的结果,吡罗替尼是一种不可逆的pan-ErbB抑制剂,在HER2阳性转移性乳腺癌患者中显示出有希望的抗肿瘤活性。